Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis (pages 825–836)
T. Dirschka, P. Radny, R. Dominicus, H. Mensing, H. Brüning, L. Jenne, L. Karl, M. Sebastian, C. Oster-Schmidt, W. Klövekorn, U. Reinhold, M. Tanner, D. Gröne, M. Deichmann, M. Simon, F. Hübinger, G. Hofbauer, G. Krähn-Senftleben, F. Borrosch, K. Reich, C. Berking, P. Wolf, P. Lehmann, M. Moers-Carpi, H. Hönigsmann, K. Wernicke-Panten, S. Hahn, G. Pabst, D. Voss, M. Foguet, B. Schmitz, H. Lübbert, R.-M. Szeimies and AK-CT002 and AK-CT003 Study Groups
Version of Record online: 25 MAR 2013 | DOI: 10.1111/bjd.12158
What’s already known about this topic?
What does this study add?
This study gives 6- and 12-month follow-up results of two pivotal phase III studies with BF-200 ALA for PDT of AK in comparison to placebo and a registered MAL cream.
It provides a comparison of recurrence rates after use of different light sources for PDT of AK.